Choice of Adjuvant Therapy in Uveal Melanoma: A Retrospective Analysis in China
L. Mao,L. Si,X. Bai,Z. Chi,C. Cui,X. Sheng,B. Lian,T. Bixia,X. Yan,J. Guo
DOI: https://doi.org/10.1093/annonc/mdx667.006
IF: 51.769
2017-01-01
Annals of Oncology
Abstract:Background: Despite effective local tumor control with radioactive plaque brachytherapy, endoresection, or enucleation, many UM (uveal melanoma) patients ultimately developed fatal metastases. This study aims to evaluate the adjuvant treatment of UM patients after surgery. Methods: Between March 2008 and Jan 2016, consecutively admitted uveal melanoma patients to Renal & melanoma department at the Beijing Cancer Hospital, were included in this cohort study. Choice of adjuvant therapy, recurrence-free survival and first metastatic sites, were analysed retrospectively. Results: In total, 97 uveal melanoma patients were investigated retrospectively. From this 97 pts, 57 were male, 47 pts had primary lesions in their left eyes, median age 46 year-old (20-72yrs). Most pts had UM arising from the choroid (97%). Seven pts were stage IV when first diagnosed. The rest 90 pts receive enucleation (61/90), endoresection (8/90), bradytherapy (21/90) respectively after initial uveal melanoma detection. Sixty-nine pts who received radical surgery of UM were divided in to observation group (n = 39), interferon group (n = 15), chemo group (n = 13), dendritic cell vaccination group (n = 2) with respect of post-surgery treatment. Of 69 pts, 57 had developed metastasis. Median replase-free survival was 2.6 years in observation group and 4.6 years in the chemo group (P < 0.05). Median replase-free survival (3.5+years) was not reached in the interferon group partly because 60% of them were admitted in recent 3 years. Liver is the most common first metastatic sites were (n = 38), the others included bone (n = 7), lung (n = 5), subcutaneous mets (n = 5). 29 pts had elevated LDH when developed distant metastasis, 9 of them were Grade 3(>5×ULN). Conclusions: Adjuvant chemotherapy or interferon might be reasonable options for patients with UM melanoma after surgery. We need more potent adjuvant therapy for this long term dormant but fatal disease. Legal entity responsible for the study: Beijing Cancer Hospital Funding: (Supported by the National Natural Science Foundation of China (81301984), Beijing Nova Program (XX2013027) and Program for New Century Excellent Talents in University (NCET-13-0007). Disclosure: All authors have declared no conflicts of interest.